Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.63 |
| ▸ | TLR2 | O60603 | 1/20 | 0.63 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.63 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.47 |
| ▸ | TFEB | P19484 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170690 | 0.87 | ERN1 (0.55) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL8598031 | 0.86 | ERN1 (0.53) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL29091959 | 0.85 | ERN1 (0.53) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL3679777 | 0.83 | ERN1 (0.54) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL28886230 | 0.83 | ALDH1A1 (0.48) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL27685686 | 0.83 | ERN1 (0.52) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL5070862 | 0.83 | LMNA (0.50) | ERN1TLR2TLR1TLR6SRC | |
| Bromomethane SCHEMBL28079811 | 0.83 | ERN1 (0.52) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL738533 | 0.81 | ERN1 (0.66) | ERN1TLR2TLR1TLR6SRC | |
| SCHEMBL30203585 | 0.81 | ERN1 (0.66) | ERN1TLR2TLR1TLR6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050112-A | DOPO derivative containing benzazepine as well as preparation method and application thereof | 西华大学 | 2023-11-14 | — | — | CN | claimed |
| CN-117050112-A | DOPO derivative containing benzazepine as well as preparation method and application thereof | 西华大学 | 2023-11-14 | — | — | CN | disclosed |
| CN-116940559-A | Cyclic diol compound, process for producing the compound, and use of the compound | 新日本理化株式会社 | 2023-10-24 | — | — | CN | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| US-8476454-B2 | IDO inhibitors and methods of use | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-07-02 | — | — | US | disclosed |
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-2246346-B1 | Indolylmaleimide derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-8277807-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| EP-1904482-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-1606285-A4 | NOVEL IDO INHIBITORS AND METHODS OF USE | LANKENAU INST MEDICAL RES (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| EP-1904482-A2 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| CN-101041660-A | 1,2-dihydrogen pyridine derivative, carbon glycosides intermediate and preparation method and application thereof | CHINESE ACAD INST CHEMISTRY (CN) | 2007-09-26 | — | — | CN | disclosed |
| US-20070173524-A1 | \"Novel ido inhibitors and methods of use | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-07-26 | — | — | US | disclosed |
| WO-2007006533-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-20060025426-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
| EP-1606285-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE | Lankenau Institute for Medical Research (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004094409-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004052315-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025426-A1 | Tyrosine kinase inhibitors | FLT1, FLT4, KDR | ERN1 1137/4885TLR2 772/4885TLR1 662/4885 |
| US-20070173524-A1 | \"Novel ido inhibitors and methods of use | IDO1, IDO2, INMT | ERN1 3427/4885TLR2 2012/4885TLR1 2239/4885 |
| US-20080318975-A1 | Indolylmaleimide Derivatives | IDH3A, INMT, IDH3B | ERN1 3370/4885TLR2 4520/4885TLR1 4573/4885 |
| US-20120251545-A1 | Therapeutic Combinations Of Hydroxybenzamide Derivatives As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | ERN1 3226/4885TLR2 2349/4885TLR1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.